The 1% game-changer for modern dairy rations.

Start at calving/freshening and feed continuously through the entire lactation. Maximum production and protection against inflammation and oxidative stress occurs when fed from day 1 postpartum onward.

Yes. All lactating cows benefit from feeding Oxyntra™ from day 1.

Year-round. Benefits on milk fat, feed efficiency, fertility, and health are seen in both thermoneutral and heat-stress conditions. Heat stress simply magnifies the antioxidant and anti-inflammatory advantages.

Yes – all dairy breeds benefit; most research is in Holsteins, but Jersey herds report even larger fat % responses.

Only under nutritionist supervision. Close-up diets are usually anionic; Oxyntra™ is strongly cationic and not suitable prepartum.

No significant interferences, but avoid mixing directly with high levels of calcium fats (palm fatty acids) – they can form soaps.

Milk fat & feed efficiency: 7–21 days. SCC, lameness, fertility, and health improvements: 30–120 days depending on herd turnover and baseline issues.

Potassium carbonate sesquihydrate (KCS) → very high +DCAD (>400 mEq/kg) → rumen pH ↑, fiber digestibility ↑, butyrate ↑ 15–30%, biohydrogenation shifted away from trans-10 intermediates. Rumen-bypass chelated Mg prevents high-K-induced Mg malabsorption → optimal Mg status for energy metabolism and antioxidant enzymes.

Combines very high-dose KCS with rumen-bypass chelated magnesium in one product → achieves >400–550 mEq/kg DCAD without causing hypomagnesemia or grass tetany risk that plain K carbonate or MgO can create.

Yes – it is a powerful alkalizer and fermentation shifter (more acetate + butyrate, less propionate/methane).

Excess reactive oxygen species (ROS) that damage cells, impair immunity, lower milk fat, reduce fertility, and drive almost every major disease. Oxyntra™ lowers systemic and local OS via butyrate (Nrf2 activator) and chelated Mg (cofactor for GPx, SOD, etc.).

Yes – all ingredients and manufacturing facilities are certified organic.

No – it is a feed additive, not a drug.

1) Higher NDF/ADF digestibility → more acetate/butyrate, 2) Direct butyrate stimulation of de novo fat synthesis, 3) Shifts biohydrogenation away from trans-10, cis-12 CLA (milk-fat-depressing isomer).

3–10 percentage unit increase in NDF/ADF digestibility + higher milk fat % → 4–8% improvement in kg ECM/kg DMI (meta-analysis of 43 trials).

Higher milk fat (+0.2–0.4%), higher ECM/feed efficiency (4–8%), lower SCC, better fertility, lower lameness, reduced HBS/sudden death events, and 5–15% lower methane intensity.

Oxyntra™ often reduces the need for sodium bicarbonate, palm fat/bypass fats (20–50% reduction possible), yeast and direct fed microbials.

Yes – 2–5% added dietary oil from distillers, soybean meal, whole soybeans, etc. is tolerated without milk fat depression because trans-10 pathways are suppressed.

Typical ROI 3–6:1. Documented gains: +0.15–0.35 lb. milk fat/day, +2–4 lb ECM/day, lower SCC premiums, reduced culling, lower vet costs → $200–450+ net profit per cow per lactation (2025 U.S. Midwest pricing).

Calves from Oxyntra™-fed dams receive higher fat colostrum/milk and are born to healthier dams → improved passive transfer, lower treatment rates, and faster growth in many cases. Allows producers to keep more cows and decrease heifer replacements with lower morbidity and mortality.

Elevated rumen/post-rumen butyrate + chelated Mg lower systemic inflammation and oxidative stress → less mammary epithelial cell death and better immune surveillance → lower SCC and reduced new intramammary infections.

Reduces oxidative stress damage to oocytes, granulosa cells, sperm, and embryos. Butyrate (HDAC inhibitor) upregulates Nrf2 antioxidant pathways and downregulates NF-κB inflammation; chelated Mg supports hormonal balance and embryo viability → higher conception rates and lower embryonic loss.

Reduces SARA → fewer LPS/histamine spikes → less lamellar inflammation. Butyrate upregulates SOD, CAT, GPx in hoof tissue; bioavailable Mg prevents hypomagnesemia-induced poor horn quality → 20–50% lower lameness incidence reported with high-DCAD + Mg strategies.

Increases rumen and hindgut butyrate supply → butyrate is the primary energy source for colonocytes → strengthens tight junctions (ZO-1, claudin, occludin) and reduces LPS translocation → less systemic inflammation and endotoxemia.

Oxyntra™ is NOT a treatment for active HBS. As a preventive, it lowers risk by (1) reducing severe SARA/hindgut acidosis, (2) increasing post-ruminal butyrate (anti-inflammatory, barrier protection), (3) maintaining Mg status and immune competence, and (4) lowering chronic inflammation that “primes” cows for Clostridium perfringens overgrowth and toxin damage.

By lowering oxidative stress and chronic inflammation throughout lactation, it reduces incidence of transition disorders, mastitis, lameness, and “sudden death” events. Farms continuously feeding Oxyntra™-type technology report markedly lower overall acute intestinal catastrophes and culling rates.

Healthier cows → fewer downer cows, less severe fatty liver/ketosis, and better body condition at dry-off → higher cull cow prices and lower involuntary culling (death loss).

Reduces enteric methane 5–15% in vivo (10–18% in continuous culture) by shifting H₂ sinks toward butyrate/acetate and suppressing methanogens. Also lowers manure methane because higher NDF/ADF digestibility leaves fewer fermentable fibers in excreta.